Introduction
MDMA (3, 4-methylenedioxymethamphetamine, ecstasy ) is a phenylethylamine derivative, with psychostimulant properties, widely " " used by young adults during night parties. MDMA has various acute effects in humans: hyperactivity, hyperthermia, cognitive disturbances, elevated anxiety, serotonin syndrome, etc. ( , , ) . Some of these effects can be Morgan, 2000 Morton, 2005 Parrott, 2002 found in animals ( , , , ) . Surprisingly, while the Callaway and Geyer, 1992 Gold and Koob, 1989 Green et al., 2003 O Shea et al., 2006 rewarding effects of MDMA have been well established in several species (monkeys, rats, mice) by the use of various paradigms, including intravenous self-administration or conditioned place preference (CPP) ( , , Lile et al., 2005 Robledo et al., 2004 , the mechanisms leading to these effects are still unclear. MDMA is a complex drug that may act on several Schenk et al., 2003 neurochemical systems. This substituted amphetamine increases the extracellular concentrations of monoamines, including dopamine (DA) and serotonin (5-HT), primarily by acting as a substrate for reuptake transporters ( , Bankson and Cunningham, 2001 Di Chiara, 1995 , , ) . Gough et al., 1991 Simantov, 2004 The endogenous opioid system is known to be involved in the processes of reward and reinforcement. The effects induced by various psychostimulants can be modulated by the opioid system ( , , ). Naltrindole Bilsky et al., 1992 Kuzmin et al., 1997 Suzuki et al., 1994 (NTI) is a selective delta-opioid receptor antagonist. The delta opioid system is notably localized in the ventral and dorsal striatum, the hippocampus and the amygdala. The implication of the delta opioid system in the effects of various drugs has been highlighted by studies showing that NTI can block or attenuate cocaine (Menkens et al., 1992;  ), morphine ( ) and Suzuki et al., 1994a Suzuki et al., 1994b levels of two delta-opioid receptor interacting peptides: pro-enkephalin ( and pro-opiomelanocortin using quantitative Penk) (Pomc) real-time PCR (Q-PCR).
Materials and methods

Animals
Male CD1 mice (20 22 g at the beginning of the experiments) (Charles River, L arbresle, France) were housed in groups of 12 in a -'
room with a 12 h light/dark cycle and temperature controlled environment (20 21 C). Food and water were provided . Animal -°ad libitum experiments were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) as well as French law, with the standard ethical guidelines and under the control of the Ethical Committee of the Faculty. Every effort was made to minimize the number of animals used and their discomfort.
Chemicals and pharmacological treatments
MDMA hydrochloride (3,4-methylenedioxymethamphetamine) was synthesized in the laboratory of Pr H. Galons (Universit Paris
and U-50,488 ( -( )-3,4-dichloro-N-methyl-N-(2-(1 pyrrolidinyl) cyclohexyl) benzeneacetamide methanesulfonate) were purchased trans + from TOCRIS (Missouri, USA). Methadone and naltrindole (NTI) were purchased from Sigma (Saint-Quentin Fallavier, France). MDMA, methadone, U-50,488, and naltrindole were dissolved in saline solution (0.9 NaCl). Naltrindole (5 mg/kg) was administered % subcutaneously (s.c.) immediately before testing. This dose was chosen on the basis of the literature, with higher doses we would have lost the selectivity of the antagonist. It has been shown that there is no dose-effect in the CPP paradigm ( ), the use of a Groblewski et al, 2008 higher dose of naltrindole would therefore alter the selectivity of this compound without changing its effect in that behavioural test. SNC80 (5 mg/kg, i.p.), methadone (3 mg/kg, i.p.) and U-50,488 (10 mg/kg, s.c.) were administered immediately before the test. These doses were chosen to ensure selectivity for their respective opioids receptors respectively. The dose of MDMA (9 mg/kg, i.p.) was chosen based on previous behavioral and transcriptional studies in the same mouse strain ( , ) . In all Salzmann et al., 2006 Salzmann et al., 2003 cases the injection volume was 0.1 ml/10 g.
Locomotor activity
The locomotor activity of mice was measured just after the drug injections during 60 min in an actimeter (Immetronic, Bordeaux, France) composed of eight cages of transparent plastic of equal size (19 11 14 cm) under low illumination (< 5 lux). One mouse was × × placed in each box to record its movements. Displacements were measured by photocell beams located across the long axis and above the floor. Locomotor activity was recorded for 60 minutes. Horizontal locomotor activities were expressed in scores (mean s.e.m) as the ± number of interruptions of the photocell beams recorded on total activity (60 min).
Conditioned Place Preference (CPP) paradigm
As previously described an unbiased place preference conditioning procedure was used ( ). The place preference Salzmann et al., 2003 apparatus consisted of two conditioning compartments (15 15 15 cm) separated by a neutral area. The conditioning compartments were × × differentiated by a distinctive sensory cue: the wall-coloring pattern (black or strips). Movements and location of mice were recorded by computerized monitoring software (Video track, Viewpoint, Lyon, France). The protocol consisted of three phases. Preconditioning phase: drug-na ve mice had free access to all compartments for 20 min, and the time spent in each compartment was recorded. Conditioning ï phase: this phase consisted of 6 days where each conditioning chamber was closed. On the first conditioning day, mice were treated with NTI (5 mg/kg s.c.) or saline just before MDMA (9 mg/kg, i.p) or saline injection according to their group and placed immediately after the last injection in one of the conditioning environments individually for 20 min. The following conditioning day, all mice were given saline in the opposite compartment, and this sequence was repeated during the next 4 days. The designation of drug-paired chamber was random and resulted in an approximately equal representation of the two conditioning chambers as the drug-paired chamber across groups for all experiments. Post-conditioning phase: this phase took place 24h after the final conditioning session (day 7). This phase was carried out exactly as the preconditioning phase. Results were expressed in scores (mean s.e.m.) calculated as the difference between the time spent ± in the drug-paired compartment during the post-conditioning phase minus the time spent in the same compartment in the preconditioning phase.
Hot plate test
The test was based on that described by Eddy and Leimbach ( ). A glass cylinder (16 cm high, 16 cm Eddy and Leimbach, 1953 diameter) was used to keep the mouse on the heated surface (52 / 0.5 C) of the plate. The latency period until the mouse jumped was For acute treatment of MDMA, mice were killed 2h after injection of the drugs, (a different group of mice had been used for behavioural study) whereas for CPP experience mice were killed the day of the test just after behavioural study, by cervical dislocation. The brain was quickly removed, frozen in isopentane at 50 C, and placed in an acrylic matrice (David Kopf Instruments, Phymep, 
eal-time quantitative PCR (Q-PCR)
The primer nucleotide sequences were chosen with the assistance of Oligo 6.42 software (MedProbe, Oslo, Norway). Sequences of the primers used for amplification were as followed: upper 5 -GCAGGGGTCTTCTCATTCC-3 and lower 5 Pomc mix. The thermal cycling conditions were 2 min at 50 C then 10 min at 95 C followed by 40 amplification cycles at 95 C for 15 sec, 65 C°°°°o r 60 C for 45 sec and 95 C for 15 sec. Quantification was made on the basis of a calibration curve using cDNA from an untreated mouse°°s triata. In addition to the genes of interest, the transcript was also quantified and each sample was normalized on the basis of its Hprt Hprt content. Results were expressed as gene of interest transcript/ transcript. Hprt
Statistical analysis
All series of data were analyzed with Statview 5.0 software (SAS Institute Inc., NC, USA). For locomotor activity, conditioned place preference and real time quantitative RT-PCR results, data were analyzed using one-way ANOVA between subjects, followed by a Bonferroni test for comparisons. The level of significance was set at <0.05. post hoc P
Results
Selectivity of the delta opioid antagonist: naltrindole
In a first series of experiments, selectivity of the delta opioid antagonist, naltrindole (5mg/kg, s.c) on opioid system was investigated.
We used opioid agonists and appropriate behavioral tests.
Delta response
The delta response was assessed with the selective delta opioid receptor agonist SNC80 using locomotor activity test. One-way ANOVA showed a significant treatment effect (F(3,36) 5.567, p<0.0033).
analysis revealed that NTI totally blocked the 
Mu response
The mu response was assessed with the mu opioid receptor agonist methadone using the hot plate test. One-way ANOVA showed a significant treatment effect (F(3,39) 77.10, p<0.0001).
analysis revealed that NTI had no effect on methadone-induced 
Kappa response
The kappa response was assessed with the kappa opioid receptor agonist U-50,488 using the locomotor activity test. One-way ANOVA showed a significant treatment effect (F(3,36 7.06, p 0.0009).
analysis revealed that NTI had no effect on U50, One-way ANOVA showed a significant treatment effect (F (3, 33) 8.345, p 0.0003) . Administration of MDMA increased = = locomotor activity as compared to saline-treated animals (saline/MDMA saline/saline). analysis revealed that NTI (5 mg/kg vs Post-hoc s.c.) was able to block this hyperactivity (saline/MDMA naltrindole/MDMA). No significant difference was found between saline/saline vs and naltrindole/saline treated animals ( ). Fig. 2 
Effect of acute MDMA and NTI administrations on Pomc and Penk mRNA levels in the striatum
The effects of naltrindole pretreatment on MDMA-induced and gene expression were analyzed by real-time quantitative Pomc Penk RT PCR ( ). In the case of , one-way ANOVA revealed significant differences in transcript levels in the striatum ( ) 
Effect of chronic MDMA and NTI administrations on Pomc and Penk gene expression in the striatum
Mice were killed the day of the test just after behavioral study. One-way ANOVA showed no significant effect of MDMA chronic ), but the mechanisms underlying these effects are still poorly understood. Few studies have focused on the Koob, 1989 Green et al., 2003 possible interaction between the delta opioid system and the effects of this substituted amphetamine ( ; Compan et al., 2003 Reid et al., ) . Indeed this system is known to be involved in the behavioral effects of various drugs of abuse such as cocaine (Menkens et al., 1996 (Menkens et al., 1992  ), morphine ( ) and methamphetamine ( ). However, only partial approaches Reid et al. 1993 Suzuki et al., 1994b Suzuki et al., 1994a have been used until now, studying either the peptides or the opioid receptors. These observations led us to study the role of the delta opioid receptor and the regulation of its interacting peptides to have an overview of the role that endogenous delta opioid system may have in MDMA-induced behaviors in mice. Since Robledo and coworkers have already shown that the rewarding properties of MDMA are preserved in mice lacking -opioid receptor, we focused on the delta system because ( ). of these peptides, and their interaction with delta opioid receptor activation might increase the dopamine release ( ) Svingos et al., 1999 leading to D1 dopamine receptor activation known to be involved in the effect of MDMA on locomotion ( ). Benturquia et al., 2008 Another possible mechanism would be that MDMA-induced increase of the extracellular levels of 5 HT and dopamine could increase -enkephalins release ( , ). Compan et al., 2003 Gobaille et al., 1994 In order to determine whether MDMA could modulate the genomic expression of delta opioid peptides, we studied the transcript levels of the precursors of the two peptides:
and . We chose to work on the dorsal striatum, this dopaminergic structure is implicated Pomc Penk in the two studied behaviours: locomotion ( , ) and reward ( , Dankova et al., 1975 Hruska and Silbergeld, 1979 Hurd and Herkenham, 1993 ). We observed that acute MDMA administration had no significant effects on the transcription level of the gene Robbins et al., 1990 Penk suggesting that these peptides are not involved in the observed behaviour. However, we cannot exclude the hypothesis that the synthesis of new enkephalins might be needless, the pre-existing pool being sufficient to mediate the action of this peptide. In the case of gene Pomc expression, data showed that MDMA-induced a decrease that was not antagonised by naltrindole. These results suggest that MDMA exerts an inhibition of gene expression in the striatum that is independent of delta opioid receptors. Pomc
In order to determine whether the delta opioid system was implicated in MDMA rewarding properties we studied the effect of naltrindole on MDMA-induced CPP. In agreement with previous studies, MDMA (9mg/kg, i.p.) induced a conditioned place preference ( ). Naltrindole significantly blocked the rewarding properties of the substituted amphetamine. These data suggest that Salzmann et al., 2003 activation of delta opioid receptors, subsequent to MDMA administration, plays an important role in the acquisition of MDMA-induced conditioned place preference consistent with an involvement of the delta opioid system in the reinforcing properties of MDMA as previously suggested by the study of Reid and coworkers ( ). Reid et al., 1996 In order to assess the expression levels of the opioid peptides during the post-conditioning CPP test, we studied their mRNA levels.
We found that, as observed after the acute treatment, the mRNA level of was not affected by chronic MDMA administration. In the Penk case of an increase of the mRNA level was found, that could be blocked by naltrindole pretreatment. The gene encode Pomc, Pomc various peptides among which -endorphin. It has been shown that -endorphin peptide plays a key role in reinforcing properties of drugs β β of abuse as cocaine ( , ), ethanol ( ), amphetamine ( ), Marquez et al., 2008 Roth-Deri et al., 2003 Marinelli et al., 2003 Olive et al., 2001 heroin ( ) and THC ( , ) . It is therefore possible that chronic MDMA treatment increases Winberg and Lepage, 1998 Zangen et al., 1999 Pomc expression through its action on 5-HT transporter.
Increase in mRNA could have been due to either the effects of repeated MDMA administration or to the effects of learning the Pomc CPP procedure. In our experimental conditions, we cannot differentiate the contributions of these two effects. The observed modulation is likely due to a combination of both effects since the learning procedure is important for the establishment of CPP.
The results of the present study demonstrate that the blockade of delta opioid receptors is able to antagonize MDMA-induced hyperlocomotion and CPP. Moreover, our molecular results suggest that chronic MDMA administration may increase the release of endogenous opioid peptides, which activate delta opioid receptors and participate in the MDMA-induced hyperlocomotion and reward.
Although, the peptide precursor affected in acute and chronic MDMA treatment is the same, the mechanisms involved seem different.
Further studies are needed to determine the implication of the -endorphin peptides in the observed modulation of the behavioral effects of β MDMA by the delta opioid system.
Figure 1
Selectivity of naltrindole (5 mg/kg) on delta, kappa and mu opioid receptors-induced behaviors Mice were injected with the delta selective agonist, SNC80 (5 mg/kg) (a) or the kappa selective agonist, U50, 488 (10 mg/kg) (c) in presence or in absence of naltrindole and were immediately placed in the actimeter to record horizontal locomotor activity for 60 min. For the mu receptor (b) mice were injected with the mu agonist, methadone (3 mg/kg, i.p.) in presence or in absence of naltrindole and were immediately placed on the hot plate. The latency period until the mouse jumped was registered. p<0.01, p<0.001 as compared to saline-saline treated ** *** group, p<0.01, p<0.001 as compared to naltrindole-saline treated group, ^^ p<0.01 as compared to saline-MDMA treated group. (n 9 ## ### = -
Figure 2
Effects of naltrindole treatment on MDMA-induced horizontal locomotor activity Mice were injected with MDMA (9 mg/kg) naltrindole (5 mg/kg) and were immediately placed in the actimeter to record horizontal ± locomotor activity for 60 min. p<0.001 as compared to saline-saline treated group, p<0.001 as compared to naltrindole-saline treated *** ### group, ^^ p<0.01 as compared to Saline-MDMA treated group. (n 9 10 per group).
= -
Figure 3
Real-time quantitative PCR of and gene expression on MDMA-induced hyperlocomotion Pomc Penk Mice were injected with MDMA (9mg/kg) naltrindole (5 mg/kg) and sacrificed 2h after treatments. Expression of ( ) and 
Figure 4
Effect of naltrindole on the acquisition of MDMA-induced CPP Mice (n 9 10 per group) received naltrindole (5 mg/kg) or saline immediately before MDMA (9 mg/kg) or saline during the conditioning = -phase. Data are expressed as mean s.e.m in score values calculated as difference between post-conditioning and preconditioning time spent ± in the compartment associated with the drug (n 10 12 per group). p<0.001 as compared to saline-saline treated group, p<0.01 as = -*** ## compared to naltrindole-saline treated group, ^^ p<0.01 as compared to saline-MDMA treated group. (n 9 10 per group).
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Figure 5
Real-time quantitative PCR of and gene expression on MDMA-induced conditioned place preference Pomc Penk Mice were conditioned with MDMA (9 mg/kg) naltrindole (5 mg/kg.). Animals were sacrificed the day of the test just after behavioral 
